SCHEDULE 13G/A: BlackRock Discloses 1.0% Stake in Kiniksa Pharmaceuticals
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.0% beneficial ownership stake in Kiniksa Pharmaceuticals International, plc, totaling 418,151 common shares.
Summary
- BlackRock, Inc. filed an Amendment No. 4 to Schedule 13G concerning its beneficial ownership in Kiniksa Pharmaceuticals International, plc.
- BlackRock, Inc. beneficially owns 418,151 shares of Kiniksa Pharmaceuticals International, plc Common Stock.
- This ownership represents 1.0% of the total class of securities.
- BlackRock, Inc. holds sole voting power over 396,136 shares and sole dispositive power over 418,151 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that acquired the security.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of an institutional ownership stake, not indicative of specific positive or negative company performance or strategic shifts for Kiniksa Pharmaceuticals International, plc.
Positives
- BlackRock, Inc.'s continued holding of shares indicates its inclusion in their investment portfolios, which can be a minor positive signal for Kiniksa Pharmaceuticals International, plc.
- The shares are held in the ordinary course of business and not for control purposes, suggesting stability and no immediate hostile intent towards the issuer.
Negatives
- The 1.0% stake is relatively small and does not indicate a strong conviction or significant new investment by BlackRock, Inc.
Future Outlook
No forward-looking statements or guidance regarding Kiniksa Pharmaceuticals International, plc's operations or financial performance are provided in this beneficial ownership report.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a routine disclosure of institutional ownership, common for large asset managers like BlackRock, Inc., reflecting their portfolio holdings in publicly traded companies. It does not provide specific industry trends or competitive analysis for Kiniksa Pharmaceuticals International, plc.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, appointing new attorneys-in-fact for executing various SEC filings and revoking a previous Power of Attorney dated April 30, 2023. | 01/21/2025 | This change relates to BlackRock, Inc.'s internal corporate governance for compliance filings and does not directly impact Kiniksa Pharmaceuticals International, plc's corporate governance. |
Stakeholder Impact
- Shareholders of Kiniksa Pharmaceuticals International, plc gain transparency regarding the beneficial ownership stake held by a major institutional investor, BlackRock, Inc.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previous Power of Attorney revoked by the new one. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 07/17/2025 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Kiniksa Pharmaceuticals, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.